Tilray | TRLY - Gross Profit On Sales

Stock Price
8.96
Daily Change
-0.44 -4.68%
Monthly
7.31%
Yearly
1,237.31%
Q2 Forecast
9.04

Tilray reported $57.47M in Gross Profit on Sales for its fiscal quarter ending in June of 2025.





Gross Profit On Sales Change Date
Acasti Pharma USD 75K 30K Mar/2021
Akebia Therapeutics USD 47.28M 1.7M Dec/2025
Alaunos Therapeutics USD -1.13M 1.11M Sep/2024
Aurora Cannabis CAD 46.62M 14.33M Dec/2025
Avita Medical AUD 14.31M 639K Dec/2025
Canopy Growth CAD 21.47M 434K Dec/2025
Cronos Group USD 16.19M 34.52M Dec/2025
Dianthus Therapeutics USD 284K 112K Dec/2025
Divis Laboratories Ltd INR 16.59B 2.05B Dec/2025
Ionis Pharmaceuticals USD 195M 40M Dec/2025
IQVIA Holdings USD 1.12B 32M Dec/2025
Knight Therapeutics CAD 64.72M 8.91M Dec/2025
Moderna USD 226M 583M Dec/2025
Organigram Holdings CAD 23.32M 8.52M Dec/2025
Organon & Co USD 854M 3M Dec/2025
Revvity USD 421.66M 47.06M Dec/2025
Tectonic Therapeutic USD 0 0 Mar/2025
Tilray USD 57.47M 10.16M Jun/2025
Viatris USD 1.15B 223.6M Dec/2025
Xeris Pharmaceuticals USD 72.15M 8.77M Dec/2025
Zealand Pharma A/S 68.91M 19.35M Dec/2025